2. Comprehensive treatment is the direction of breast cancer treatment, and the situation of "one-two punch" of surgery has become the past, and the one-sided promotion of the role of surgery and the worship of the idea of "one-size-fits-all" are all wrong. Clinical trials have shown that postoperative adjuvant therapy for breast cancer can reduce recurrence in 1/3 of the cases and lower the 10-year mortality rate by 1/6 to 1/5. The comprehensive treatment of breast-conserving surgery plus radiotherapy and chemotherapy for early-stage breast cancer is the same as that of radical surgery and modified radical surgery in terms of local and regional control rate and long-term survival rate, but it improves the quality of life of patients. The stereotypical "silo" approach of physicians should be avoided in combination therapy. Surgery, radiotherapy, chemotherapy, pathology doctors should pay attention to the overall rational design of the treatment plan and the organic cooperation between the various therapies, unity and collaboration to ensure the success of integrated treatment.
3. Standardized treatment is the key to the success or failure of breast cancer treatment, which should be strongly advocated and strengthened in China. In Europe and the United States, there are corresponding comprehensive treatment guidelines (Guide line) for each stage of breast cancer. The proposal of standardized program is based on "evidence-based medicine" and is based on the results of prospective randomized clinical trials. One of the reasons why the level of breast cancer treatment in China lags behind that in Europe and the United States is that it is not standardized. The treatment methods are very inconsistent, and the treatment effects are very different. Surgeries abandoned abroad are still done in China, and technologies popularized abroad are only carried out in a few hospitals in China. The standardization of breast cancer treatment is closely related to factors such as socio-economic status, national medical facilities and ethnicity. Breast-conserving surgery is the first choice for early breast cancer in Europe and the United States, but in the American countryside, because some patients cannot complete all the conventional treatments, surgeons do not follow the principle of breast-conserving treatment proposed by the NSABP, and tend to perform a total mastectomy.Paik et al. reported that the efficacy of breast-conserving treatment for breast cancer among Korean women was better than that of the same period in Europe and the United States, as shown in the 21st International Breast Cancer Conference in San Antonio and the 3rd Asian Breast Cancer Conference. Paik et al. reported in the 21st San Antonio International Breast Cancer Conference and the 3rd Asian Breast Cancer Conference that breast-conserving treatment for Korean women with breast cancer was more effective than the breast-conserving treatment groups in the same period in Europe and the United States. Whether breast cancer in Asian women is different from that in Western women needs to be investigated. Breast-conserving surgery requires high medical technology, radiotherapy equipment and treatment cost, so it should not be carried out reluctantly in some hospitals that do not have the conditions in China. In conclusion, the standardization of breast cancer treatment should not completely copy the treatment models of Europe and the United States, but should take into account China's medical resources and needs to develop appropriate treatment standards. So far, there is no surgery that can be applied to all stages and parts of breast cancer. Therefore, while emphasizing standardized treatment, we should also follow the principle of individualized treatment. Under the guidance of surgeons, breast cancer patients can choose the most ideal option from different treatment plans, and multidisciplinary integrated treatment teams will play an important role in individualized breast cancer treatment. 4. It is foreseen that in the coming period, the treatment of breast cancer will see the coexistence of several kinds of surgeries, and an individualized integrated treatment model that takes into account both cure and quality of life. Breast-conserving surgery plus sentinel lymph node biopsy has become the first choice of early breast cancer treatment in Europe and the United States. In China, due to the lack of popularization of radiotherapy equipment and technology, it is only carried out in a few hospitals, but it will become the development trend in the future. Modified radical surgery is still dominant in China, but it will be replaced by breast-conserving surgery. The safety of immediate breast reconstruction has been confirmed, and it does not affect the prognosis and follow-up of breast cancer patients, so it will have its development space in the conditioned hospitals and patients' demand. Surgery can improve the local and regional control rate of breast cancer treatment and reduce the recurrence rate. Neoadjuvant chemotherapy, radiotherapy, consolidation chemotherapy, endocrine therapy and biotherapy can further reduce recurrence and death, and improve survival rate. Clinical prognostic indicators and tumor marker tests can help determine the intensity of adjuvant therapy. Breast cancer surgery will continue to seek its place and value in the comprehensive treatment, and keep pace with the times. Breast surgeons will also take stock of the situation and continue to improve the new meaning of breast cancer surgery.